Digoxin API supply secured through acquisition

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags: API, acquistion, Supply chain, India

C2 Pharma acquires digoxin API product portfolio from Noblius to secure supply of the ingredient, after disruption of the supply of the API for a number of years.

C2 Pharma, a Luxembourg-based phytochemical and chemical-pharmaceutical company, secured its supply of the active pharmaceutical ingredient (API) digoxin, through the acquisition of Nobilus’ API product portfolio.

The availability of digoxin API has been disrupted since 2014. Marcelo Reinhardt, senior director of business development at C2 Pharma, told us the disruption has been “due to the inability of the manufacturers and their digitalis leaf growers to supply the marketplace reliably.”

Per the acquisition, a full supply of the API will be available from C2 Pharma through two sources of manufacturing with its partners Nobilus in Poland and Laurus Labs in India.

To mitigate the risk of unreliable product posed with the manufacture of digoxin, C2 Pharma will set up a fully independent supply chain and continue to invest in a dedicated manufacturing facility for Laurus Labs.

The company invested around $10m (€8.84m) in the fully dedicated production facility at Laurus site in Vizag, India.  According to Reinhardt, the plant is 1,800m2 ​and has an annual production output which covers the global demand for digoxin.

This agreement sees C2 Pharma become the owner of the API product portfolio and Nobilus become its manufacturing and distribution group. Reinhardt explained that while Digoxin does not have a large market, it is a niche but global API and is classified as an essential drug by the World Health Organization. 

Related news

Related products

show more

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us

Products

View more

Webinars